Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -74.6%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $3M | $3M | $4M | $8M | $14M | — | — | — | — | — |
| Enterprise Value | $-2751060 | $-1898728 | $-630256 | $910712 | $-3691971 | $4M | — | — | — | — | — |
| P/E Ratio → | -0.24 | — | — | — | — | 5.50 | — | — | — | — | — |
| P/S Ratio | 27.71 | 39.53 | 45.43 | 61.51 | 106.45 | 192.48 | — | — | — | — | — |
| P/B Ratio | 0.16 | 0.45 | 0.65 | 0.72 | 0.74 | 1.51 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -26.33 | -8.74 | 12.63 | -51.20 | 54.44 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | 0.93 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 0.93 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1128.9% | -1128.9% | 91.9% | 91.9% | 91.9% | 93.0% | — | 32.5% | — | 100.0% | 100.0% |
| Operating Margin | -5937.0% | -5937.0% | -6526.4% | -5347.4% | -5031.3% | -3851.0% | — | -2293.4% | — | -55.5% | 58.8% |
| Net Profit Margin | -5863.5% | -5863.5% | -6092.6% | -5132.6% | -5420.9% | 5477.9% | — | -2497.7% | — | 42.1% | 166.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.6% | -74.6% | -78.4% | -44.8% | -40.3% | 75.5% | -483.0% | -527.0% | -120.4% | 34.8% | -79.3% |
| ROA | -56.3% | -56.3% | -58.0% | -38.2% | -35.3% | 65.5% | -316.3% | -150.2% | -77.7% | 24.2% | -59.4% |
| ROIC | -239.1% | -239.1% | -186.7% | -355.6% | — | — | -3355.0% | -6862.1% | -89.0% | -60.0% | -39.3% |
| ROCE | -67.4% | -67.4% | -74.0% | -42.4% | -34.2% | -48.6% | -264.9% | -157.1% | -49.3% | -33.0% | -21.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.01 | — | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.75 | -0.78 | -0.57 | -1.10 | -1.09 | -0.87 | — | -0.77 | -0.24 | -0.68 |
| Net Debt / EBITDA | — | — | — | — | — | -2.35 | — | — | — | -0.83 | -1.78 |
| Debt / FCF | — | — | — | — | — | — | — | — | -1.15 | — | — |
| Interest Coverage | -112.34 | -112.34 | -863.06 | -744.76 | -1775.89 | 1378.47 | -8.90 | -15.10 | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.36 | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 10.07 | 4.23 | 13.05 | 42.81 | 12.52 |
| Quick Ratio | 11.36 | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 9.83 | 2.89 | 12.49 | 42.81 | 12.52 |
| Cash Ratio | 10.55 | 10.55 | 4.28 | 9.88 | 26.06 | 20.93 | 7.96 | 1.04 | 11.78 | 7.68 | 10.91 |
| Asset Turnover | — | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.08 | — | 0.52 | -0.52 |
| Inventory Turnover | — | — | — | — | — | — | — | 0.18 | 0.65 | — | — |
| Days Sales Outstanding | — | — | — | — | 334.16 | — | — | 1799.40 | — | — | -31.92 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 18.2% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 5.3% | 10.6% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 5.3% | 10.6% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $558818 | $245359 | $205325 | $152283 | $127896 | $87940 | $56153 | $65469 | $69443 | $66928 |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SILO stock.
Silo Pharma, Inc.'s current P/E ratio is -0.2x. The historical average is 5.5x.
Silo Pharma, Inc.'s return on equity (ROE) is -74.6%. The historical average is -70.3%.
Based on historical data, Silo Pharma, Inc. is trading at a P/E of -0.2x. Compare with industry peers and growth rates for a complete picture.
Silo Pharma, Inc. has -1128.9% gross margin and -5937.0% operating margin.
Key Metrics
Top Statement Risk
Dilutive financing dependency
Metrics are mathematically derived from official filings.
Speculative Premium Amid Revenue Scarcity
According to recent market data, SILO trades at a P/S ratio of 75.85, a figure that appears disconnected from fundamental performance and suggests investors are pricing in the potential of the delivery platform rather than any current commercial output or historical revenue generation.
The elevated P/S multiple reflects the market's attempt to value the company as a technology platform rather than a traditional pharmaceutical entity. Investors should monitor whether this valuation can be sustained as the company approaches clinical milestones, as the lack of forward P/E or EBITDA multiples highlights the absence of a clear path to near-term profitability.
Persistent Erosion of Invested Capital
As reported in financial statements, SILO's ROIC has remained deeply negative, reaching -71.7% in 2026Q1, which indicates that the company is currently destroying shareholder value as it consumes capital to fund research without generating any offsetting returns on its invested assets.
The consistent decay in ROIC is a direct consequence of the company's developmental stage, where capital is deployed into high-risk clinical trials with no immediate commercial return. This trend warrants further investigation into whether the company's proprietary delivery mechanisms can eventually achieve the scale necessary to reverse these negative returns.
Shrinking Runway Amid Clinical Expansion
Based on the reported figures, SILO's current ratio has declined from 9.90 in 2023Q4 to 9.65 in 2026Q1, signaling that while the company maintains a high liquidity buffer, the absolute cash position is under pressure from rising R&D expenditures.
The high current ratio is somewhat misleading, as it is primarily a function of the company's lack of significant short-term liabilities rather than an abundance of operational cash. Investors should monitor the burn rate closely, as the current liquidity position may be insufficient to support the company through the completion of its active clinical trials.
Valuation Divergence Within Micro-Cap Peers
As noted in industry comparisons, SILO's P/B ratio of 0.54 sits significantly below peers like Cybin Inc., which trades at 6.52, suggesting that the market may be applying a substantial discount to SILO's book value due to its unique history and current developmental focus.
This valuation gap may indicate that the market is skeptical of the company's transition from its legacy consumer brand to a biotech firm. The structural difference in how the market prices SILO compared to its peers suggests that the company's intellectual property and delivery platform have yet to gain the same level of institutional credibility.
Misapplication of Traditional Revenue Multiples
Analysis of the business model suggests that the P/S ratio is the most commonly misapplied metric for SILO, as it obscures the company's true nature as a pre-revenue research entity and fails to account for the potential value of its proprietary CNS-homing peptide platform.
Using revenue-based multiples for a company that lacks a commercial product is fundamentally flawed and provides little insight into the company's actual progress. Instead, investors should focus on clinical trial enrollment velocity and patent milestones, which serve as more accurate indicators of the company's long-term viability and potential for future licensing revenue.